Shashikant B Lele MD
Gynecologic Oncology
Clinical Professor of Obstetrics & Gynecology, SUNY Buffalo
Join to View Full Profile
Elm And Carlton StBuffalo, NY 14263
Phone+1 716-845-2300
Fax+1 716-845-7608
Dr. Lele is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University at BuffaloFellowship, Gynecologic Oncology, 1974 - 1976
The MetroHealth System/Case Western Reserve UniversityResidency, Obstetrics and Gynecology, 1971 - 1973
Cleveland Clinic FoundationInternship, Transitional Year, 1970 - 1971
Grant Medical CollegeClass of 1965
Certifications & Licensure
NY State Medical License 1974 - 2026
OH State Medical License 1974 - 1974
American Board of Obstetrics and Gynecology Obstetrics & Gynecology- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- Buffalo Spree Magazine Castle Connolly, 2006, 2008, 2010, 2013-2014
- America's Top Doctors for Cancer Castle Connolly, 2007-2013
- Join now to see all
Clinical Trials
- Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer Start of enrollment: 2007 Feb 01
- Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
Publications & Presentations
PubMed
- mTOR inhibition modulates vaccine-induced immune responses to generate memory T cells in patients with solid tumors.Henry G Withers, Junko Matsuzaki, Mark Long, Spencer R Rosario, Thinle Chodon
Journal for Immunotherapy of Cancer. 2025-03-25 - Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.Ramez N Eskander, Michael W Sill, Lindsey Beffa, Richard G Moore, Joanie M Hope
Nature Medicine. 2025-03-05 - Prognostic significance of serum complement activation, neutrophil extracellular traps and extracellular DNA in newly diagnosed epithelial ovarian cancer.Jason Ricciuti, Qian Liu, A N M Nazmul H Khan, Janine M Joseph, Bert Veuskens
Gynecologic Oncology. 2025-02-01
Press Mentions
Surgical-Pathological Findings in Type 1 and 2 Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study on GOG-210 ProtocolJune 1st, 2017
Women Who Received HPV Vaccine May Need Another ShotApril 24th, 2015
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
